Long term outcomes of simple clinical risk stratification in management of differentiated thyroid cancer. Issue 5 (October 2018)

• Record Type: Journal Article
• Authors: Craig, W.L.; Smart, L.; Fielding, S.; Ramsay, C.; Krukowski, Z.H.
• Is Part Of: Surgeon. Volume 16:Issue 5(2018)
• Page Start: 283
• Page End: 291
• Publication Date: 2018-10
• Subjects: Thyroid cancer -- Surgery -- Risk management -- Conservative therapy; Surgery -- Periodicals; Surgery -- Periodicals; Surgical Procedures, Operative -- Periodicals; 617
• DOI: 10.1016/j.surge.2018.01.007
• Languages: English
• ISSNs: 1479-666X

Abstract

Abstract: Objective: To establish the long term outcomes of risk stratified management of differentiated thyroid cancer (DTC). Background: Guidelines for management of DTC lack a strong evidence base and expose patients to overtreatment. This prospective study of patients diagnosed with DTC between 1977 and 2012 describes the long term outcomes of a conservative risk stratified (AMES) management policy. Methods: Outcomes were analysed around patient and tumour characteristics, primary intervention (surgery ± radioiodine (RAI)), in terms of mortality, recurrence and reintervention. Results: Median follow-up in 348 patients was 14 years: mean age 48 (range 10–91) years, 257 (73.9%) female, 222 (68.3%) papillary cancer, tumour size 3.4 ± 2.0 cm (mean ± SD). 89 (25.6%) AMES high risk, 116 (33.3%) TNM stage III/IV and 16 (4.6%) had distant metastases. Primary surgery comprised lobectomy in 189 (54.3%): 11 (5.8%) patients had subsequent completion total thyroidectomy with cancer present in five. Primary nodal surgery was performed in 142 (40.8%) patients. 35 (13.5%) low and 43 (48.3%) high risk patients received RAI following initial surgery. Overall disease specific survival (DSS) was 92.1% at 10 years and 90.7% at 20 years. DSS at 20 years was 99.2% in low risk cases. AMES risk scoring predicted both survival and recurrence. Patients receiving RAI and AMES high risk were significantly associated with increased risk of death and recurrence. Conclusions: Routine total thyroidectomy and RAI are not justifiable for low risk DTC. Treatment should be tailored to risk and AMES risk stratification remains a simple reliable clinical tool.